Introduction
The Philadelphia (Ph þ ) chromosome identifies a subset of acute lymphocytic leukemia (ALL) that occurs in 2-4% of children with ALL and carries a poor prognosis. The probability of curing childhood ALL with chemotherapy is 75-80%. However, only 20% of children with Ph þ ALL are cured with chemotherapy. [1] [2] [3] This dismal outcome has not improved in the last several decades.
Matched sibling allogeneic bone marrow transplants are the treatment of choice for Ph þ ALL. The 5-year survival with such transplants is 72%. 4 However, most patients lack a suitable sibling donor. Recently, a few studies have reported success with matched unrelated bone marrow transplants. The 2-year relapse-free survival is 37-50%. However, post transplant relapse is the main cause of failure with relapse rates between 40 and 60%. 5, 6 In this paper, we report our experience with alternative donor transplantation in children with Ph þ ALL. Prior to 2001, donor selection was based on serologic typing for class I antigens using standard microcytotoxicity assays to detect HLA-A and HLA-B antigens currently recognized by the World Health Organization (WHO). 7 HLA-DR and DQ compatibility was assessed by either oligotyping or DNA sequence analysis using previously described techniques prospectively starting in 1990 (UPN 301 and higher), and retrospectively for all other cases. 8 DNA sequencing was used to prospectively type HLA-A and HLA-B locus alleles beginning in 2001 (UPN 1351 and higher) and was expanded to include HLA-C typing for donor selection in 2002 (UPN 1422 and higher). Many donor/recipient pairs prior to 2001 were retrospectively analyzed with more discriminating HLA methodologies (i.e., isoelectric focusing and/or DNA sequencing) for Class I alleles and Class II in the context of other studies as indicated in Table 2 . Assignments of HLA donor/recipient histocompatibility represent the optimal resolution of HLA disparities known at the time of latest clinical follow-up. Any HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ donor/recipient disparity that was detectable by serology, IEF, oligotyping, or DNA sequence analysis was considered a mismatch.
Patients, materials and methods

Patient population
Preparative regimen, GVHD prophylaxis and supportive care All patients were treated in HEPA-filtered rooms. Pretransplantation conditioning consisted of high-dose cytosine arabinoside (3 gm/m 2 Â 6, day À7 to day À4), cyclophosphamide (45 mg/kg Â 2, day À6 and day À5), and methylprednisolone (1 gm/m 2 Â 4, day À2 to day 0). Fractionated total body irradiation (day À2 to day 0) was given to a total dose of either 13.32 (2 fractions/day Â 3 days) Gy (n ¼ 10) or 14 (3 fractions/day Â 3 days) Gy (N ¼ 19). 9, 10 All patients had shielding of lungs, liver, and kidneys to reduce radiation exposure to these vital organs. 11 In addition, seven patients also received busulfan (4 mg/kg Â 2, day À9 and day À8). One patient had etoposide (150 mg/m 2 Â 3 doses) added to his conditioning. In total, 23 patients received unrelated donor marrow while six patients received marrow from a mismatched family member. All patients had a partially T-cell-depleted (TCD) transplant using antibody/complement techniques as previously described 12 plus post transplant cyclosporin. The T-cell depletion method from 1987 to 1998 consisted of ex vivo TCD with the ab T-cell receptor antibody, T 10 B 9 , and baby rabbit complement (N ¼ 25). 13 Owing to unavailability of T 10 B 9 thereafter, ex vivo TCD was performed with OKT3 antibody plus complement beginning in October 1998 (N ¼ 4). The T-cell dose administered was measured in 19 of the 29 patients in the study with a median of 3. /kg. Two patients (UPN 1422, 1434) received short course methotrexate for GVHD prophylaxis in combination with the partial TCD and CSA as described by Marks due to 8/10 mismatch in UPN 1434 and suboptimal T-cell depletion in UPN 1422. 14 The six patients with a partially mismatched family donor received additional GVHD prophylaxis with ATG (ATGAM; 15 mg/kg/day days 4-17) and glucocorticoids (methylprednisone 2 mg/kg/day weaned by day 35). 15 All patients received prophylactic antimicrobials, antivirals, and antifungals according to institutional guidelines. CMV monitoring was performed by CMV Antigenemia when it became available in 1998 and via CMV PCR in 2003. CMV therapy was instituted once a patient showed evidence of reactivation of CMV.
Assessment of engraftment, GVHD, relapse, and overall survival The date of engraftment was defined as the first of 3 consecutive days in which the absolute neutrophil count (ANC) X500/mL. Acute GVHD was graded as 0-IV according to the criteria of Glucksberg et al., 16 whereas chronic GVHD was defined as none, limited, or extensive. 17 Patients who had evidence of engraftment were evaluable for acute GVHD, whereas patients who engrafted and also survived more than 100 days were evaluable for chronic GVHD. Transplant-related mortality (TRM) was defined as death resulting from any cause other than relapse. Early TRM is defined as occurring on or before day 100; late TRM is defined as TRM occurring after day 100. Relapse was defined by either morphologic evidence of disease in the peripheral blood, marrow, extramedullary sites, or by the recurrence and sustained presence of pre-transplantation chromosomal abnormalities based on cytogenetic analysis of bone marrow cells. Patients who died from complications of a second transplantation or donor leukocyte infusion therapy given for recurrent disease were deemed to have died from disease relapse. Patients who died of complications from a second transplantation for graft rejection were classified as having died from graft rejection. The probability of overall survival was calculated using the Kaplan-Meier estimator. 18 
Results
Patient characteristics
The patient characteristics are summarized in Table 1 . The median age was 10.5 years (range 2.5-20 years). The median WBC at diagnosis was 35 600 (range 3100-665 000). There were 16 male and 13 female subjects. A total of 18 patients were in CR 1, five were in CR 2, one was in CR 3, and the remaining five had refractory disease at the time of transplantation.
Donor characteristics
HLA matching criteria at the time patients in this study were transplanted considered only HLA-A, B, DRB1, and DQ. Retrospective high-resolution typing revealed additional disparities not known at the time of transplant. Donor/recipient HLA disparity is shown in Table 2 .
Engraftment
All patients engrafted with a median time to an ANC of 0.5 Â 10 9 /l of 16 days (range, 7-29 days). One patient lost his graft 4 days after primary engraftment due to HHV-6, but was successfully regrafted with the same donor. A platelet count of 100 Â 10 9 /l was achieved by 19 of 29 patients in a median of 33 days (range, 15-185 days). Four patients required more than 100 days. Chimerism studies performed after transplantation consistently showed complete engraftment of donor cells in all 24 patients who were tested. Six patients were tested by XX/XY FISH studies and 18 patients were tested by VNTR.
Graft-versus-host (GVHD) disease GVHD incidence and severity is summarized in Table 3 . A total of 14 patients developed grades 2-4 acute GVHD and of these, four developed grades 3-4 acute GVHD. Among the 24 survivors in remission for more than 100 days, eight patients (33%) developed chronic limited GVHD and three patients (13%) developed chronic extensive GVHD. Five patients died from complications resulting from GVHD: three with acute GVHD at days 41, 74, and 99 and two with chronic GVHD at days 182 and 380. Of these five patients, their HLA disparities included (UPN 101) HLA A, B, C, DRB1, DQ disparities; (UPN 272) DRB1 and 2 DQ disparities; (UPN 477) HLA A disparity; (UPN 776) 5 disparities at HLA A, B and C; (UPN 1434) disparities at HLA B, C.
Relapse
Two of 29 (7%) patients relapsed; one patient at day 100 and another patient at 1-year post transplant. Both patients eventually died from their leukemia.
TRM
Of 29 patients, 14 (48%) died from treatment-related complications. Six patients died from early TRM and eight patients died from late TRM. As stated above, five patients died from complications resulting from GVHD. Two patients died of glioblastoma multiforme, 84 and 102 months post transplant. Neither patient had received cranial irradiation prior to the transplant preparative regimen. One patient died of EBV-post transplant lympho- proliferative disease at day 94. Two patients died of ARDS at day 71 and 261. Four patients died of infection: CMV (n ¼ 2) at day 66 and 163, aspergillus (n ¼ 1) at day 123, clostridium septicum (n ¼ 1) at day 191.
Survival Figure 1 shows that the Kaplan-Meier probability of survival at 3, 5, and 10 years was 56%79.6, 51%79.6 and 46%710.2, respectively, for the full cohort. Eight of 18 patients transplanted in CR1, four of five patients transplanted in CR 2, and one of six patients transplanted in 4CR 2 remain alive and leukemia free at a median follow up of 10 years, range (14-198 months) . The Karnofsky score is 100% in all survivors. Long-term complications that had occurred in the survivors included cataracts n ¼ 5, growth hormone deficiency n ¼ 4, gonadal failure n ¼ 4, hypothyroidism n ¼ 3, learning disability n ¼ 2, avascular necrosis n ¼ 1, BMT nephropathy n ¼ 2, hypertension n ¼ 1, insulin-dependent diabetes mellitus n ¼ 2, restrictive lung defect n ¼ 3, hemorrhagic cystitis n ¼ 1, bronchiolitis obliterans n ¼ 1, CMV retinitis n ¼ 1, and melanoma of the buttocks n ¼ 1.
Discussion
Arico et al. 4 reviewed the outcomes of 326 children with Ph þ ALL treated by 10 cooperative groups or large single institutions from 1986 to 1996. Patients who entered remission were divided into three prognostic groups: best prognosis included patients with age p10 years and WBCo50 000/ml (n ¼ 95), worst prognosis included patients at any age who had an initial WBC4100 000/ml (n ¼ 92) and intermediate prognosis included all others (n ¼ 80). Disease-free survivals at 5 years (7s.e.) were 4975% (best prognosis), 3075% (intermediate prognosis), and 2075% (worst prognosis). Transplantation from an HLA-matched related donor resulted in a significantly better outcome than chemotherapy alone for all prognostic subgroups combined (6578 vs 2574%, respectively). The advantage of matched sibling transplantation was also seen (though not always significant) in each prognostic subgroup. In contrast, transplantation of Alternative donor BMT for children with Ph þ ALL JM Talano et al marrow from mismatched related donors and matched unrelated donors was slightly inferior (not statistically significant) to treatment with chemotherapy alone due to an excess number of transplantation-related deaths. Our single center experience suggests that alternative donor transplantation for children with Ph þ ALL may be an option for patients in first or second remission, who do not have a matched related donor, particularly in patients with intermediate and worst prognostic factors. Other small series have concurred that alternative donor transplant is an effective treatment option for patients with Ph þ ALL. Sierra et al. 6 reported outcomes in 18 children. Their conditioning regimen included cyclophosphamide (60 mg/ kg Â 2 days) and total body irradiation (14.4 Gy in 12 fractions). Infused marrow was T-cell replete. In 12 cases, GVHD prevention consisted of cyclosporine and methotrexate, methotrexate and FK506 for three patients, cyclosporine plus methotrexate and humanized monoclonal antibody against the interleukin-2 alpha chain receptor (anti-Tac) for one patient, and T-cell depletion of the marrow plus cyclosporine and methotrexate post transplant for two patients who received marrow from one-antigen mismatched donors. Leukemia-free survival was 49712% at 2 years. Five patients died from recurrence of leukemia. Marks et al. 5 reported on 15 children and adolescents who received T-cell-depleted unrelated donor bone marrow transplants for Ph þ ALL. Their conditioning regimen included cyclophosphamide (60 mg/kg Â 2 days), total body irradiation (14.4 Gy in eight fractions), and Campath (5-10 mg twice a day for 5 days). GVHD prophylaxis consisted of cyclosporine from day À1 to 6 months post transplant. Seven patients also received three doses of intravenous methotrexate on day 1, 3, and 6. The 2-year overall and disease-free survivals were 44713 and 37713%, respectively. Six patients died from recurrence of their leukemia.
Our report describes the outcomes of 29 children with Ph þ ALL who received alternative donor transplants between 1987 and 2002. We had a strikingly low relapse rate (2/29; 7%) compared to other reports (28-40%). 5, 6, 9 Our treatment approach attempts to balance a very intense conditioning regimen with a partially T-cell-depleted allograft. 19 Pre-transplant conditioning includes high-dose cytosine arabinoside in addition to cyclophosphamide and TBI. The addition of cytosine arabinoside may confer an additional antileukemic effect. Additionally, partial T-cell depletion, as compared to other more rigorous methods of depletion, may leave behind a fraction of T cells, which possess an antileukemia effect. However, the intensity of treatment may contribute to the high TRM and the late effects seen in our study.
There was a considerable degree of donor/recipient HLA disparity in our patients, most of which was revealed only by retrospective high-resolution typing methods. Two antigen disparities in the recipients of unrelated grafts appeared to be well tolerated in this pediatric patient group. The presence of HLA disparity (two antigen) may have contributed to the lower relapse rate as compared to recipients of HLA identical sibling grafts for Ph þ ALL reported by others due to a graft versus leukemia effect.
Our data suggest that patients who enter transplantation with refractory disease or are beyond a second complete remission do poorly. Five out of six patients who were transplanted in 4CR 2 or relapse died.
This report documents the longest median follow-up for such a cohort. This long-term follow-up (median 10 years) clearly demonstrates the durability of remission post transplantation. Equally important, with such long follow up, we are able to assess the late effects of treatment. Two patients developed glioblastoma multiforme, 7 and 8.5 years post transplant. These are the only two patients in our cohort of 110 pediatric leukemic patients transplanted using alternative donors and surviving more than 5 years who developed malignant brain tumors. Arico et al. 4 reported that two of 120 children with Ph þ ALL developed malignant brain tumors: a glioma 5.9 years after a mismatched related donor transplant and an astrocytoma 4.8 years after an autologous transplant. Other studies indicate that the cumulative incidence of secondary brain cancer after conventional therapy for ALL is typically between 0.5 and 2.0%. 20, 21 However, this has been associated with the presence of CNS leukemia, cranial spinal irradiation and age o10 years at the time of treatment. Neither of our two patients had CNS disease nor received additional cranial radiation and both were over the age of 15 years. One explanation might be a predisposition of patients with Ph þ ALL to develop secondary brain tumors. However, since the vast majority of patients treated with chemotherapy alone die from recurrent disease, such a predisposition, if it exists, may have been missed. Prolonged follow-up of large transplanted and nontransplanted cohorts is needed to answer this question.
Other late effects seem to be correlated with the total body irradiation, which included cataracts, growth hormone deficiency, gonadal failure, hypothryoidism, IDDM, and pulmonary complications (restrictive lung defects and Bronchiolitis obliterans). The probability of developing cataracts after TBI is 50% at 10 years; however, Belkacemi et al. 22 analyzed 2149 patients in the EBMT registry. They showed that the incidence varies based on how the TBI was delivered. In their study, the incidence of cataracts was 60% in the single dose TBI group, 43% in the fractionated TBIp6 fractions, and 7% in the fractionated TBI46 fractions. 22 During the course of this cohort, we have increased our TBI fractions from 6 to 9 in order to minimize the late effects. We have also seen in addition to the brain tumors, one other secondary malignancy in our cohort: melanoma of the buttocks. Melanoma is a welldescribed secondary malignancy post transplantation. 23 We are currently reducing our total TBI dose from 1400 to 1200 cGy in an attempt to minimize these late effects.
Our experience with this cohort ranges from 1987 through the present. Advancements in supportive care have led to earlier detection of both CMV reactivation and EBV PTLD, so that preemptive therapy can be instituted. Clearly, over this time period, advancements have been made in the use of chemotherapy for Ph þ ALL as well as the molecular detection of minimal residual disease which may improve the outcomes for all children with Ph þ ALL. [24] [25] [26] As new treatments are developed, the role of transplantation in the treatment of Ph þ ALL will require continued reassessment. Based on the data sited above, we currently believe that alternative donor BMT should be considered early in the treatment of a child or young adult with Ph þ ALL. We recommend identifying the best alternative donor source early in the patient's treatment course as well as careful monitoring of minimal residual disease once the patient enters CR1. Ideally, this tactic will capture the patient in morphologic CR1 who has increasing minimal residual disease before the leukemia proceeds to a morphologic relapse. We believe this strategy takes advantage of advancements in nontransplant treatment and monitoring, as well as recognizing that alternative donor BMT is a reasonable and recommended option for children and young adults who do not have an HLA matched sibling. This approach would optimize patient selection for alternative donor transplantation by recommending it to those patients who are at high risk for relapse who have an acceptable donor. This strategy has a two-fold purpose: it limits transplantation to those patients who clearly need it for leukemia control and hopefully it will decrease treatment-related morbidity and mortality by taking patients to transplantation earlier in their treatment course. Ultimately, with advances in molecular/genetic testing, we would hope to identify these patients at diagnosis.
